Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on April 30, 2024, the company granted equity awards to ten new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
波士頓，2024 年 5 月 3 日（GLOBE NEWSWIRE）— Verve Therape是一家處於臨床階段的生物技術公司，開創了使用單療程基因編輯藥物治療心血管疾病的新方法。該公司今天宣佈，根據公司2024年的激勵股票激勵計劃，公司於2024年4月30日向十名新員工發放了股權獎勵，作爲根據納斯達克上市規則5635（c）（4）在公司工作的每位新員工的激勵材料。
The employees received stock options to purchase an aggregate of 64,200 shares of the company's common stock and an aggregate of 56,100 restricted stock units (RSUs). The options have an exercise price of $6.01 per share, which is equal to the closing price of the company's common stock on the date of grant. Each option has a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, subject to each such employee's continued service with the company on each such vesting date. The RSUs will vest in equal annual installments on the first four anniversaries of July 1, 2024, subject to each such employee's continued service with the company on each such vesting date.
員工獲得了股票期權，總共購買了64,200股公司普通股和總共56,100個限制性股票單位（RSU）。這些期權的行使價爲每股6.01美元，等於授予之日公司普通股的收盤價。每種期權的期限爲10年，將在四年內歸屬，其中25％的股份在授予日一週年之際歸屬，其餘的股份將在接下來的三年中按月等額分期歸屬，視每位此類員工在每個此類歸屬日期繼續在公司服務而定。RSU將在2024年7月1日的前四個週年紀念日按年等額分期付款，前提是每位此類員工在每個此類歸屬日期繼續在公司任職。
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company's lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally-tolerated standard of care therapies. For more information, please visit www.VerveTx.com.
關於 Verve Therapeu
Verve Therapeutics, Inc.（納斯達克股票代碼：VERV）是一家臨床階段的基因藥物公司，開創了一種新的心血管疾病護理方法，有可能將治療從慢性治療轉變爲單療程基因編輯藥物。該公司的主要項目 — VERVE-101、VERVE-102 和 VERVE-201 — 靶向的基因已被廣泛驗證爲降低低密度脂蛋白膽固醇 (LDL-C) 的靶標，低密度脂蛋白膽固醇是動脈粥樣硬化性心血管疾病 (ASCVD) 的根本原因。VERVE-101 和 VERVE-102 旨在永久關閉 PCSK9 肝臟中的基因，最初是針對雜合子家族性高膽固醇血癥（HeFH）而開發的，最終用於治療仍受高低密度脂蛋白-C水平影響的已確立ASCVD的患者。VERVE-201 旨在永久關閉 ANGPTL3 肝臟中的基因，最初是針對純合子家族性高膽固醇血癥（HoFH）和難治性高膽固醇血癥開發的，在這些情況下，儘管使用最大耐受性標準的護理療法進行治療，但患者的低密度脂蛋白水平仍然很高。欲了解更多信息，請訪問 www.vervetx.com。
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
投資者聯繫人
詹·羅賓遜
Verve Thareutics, Inc
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
媒體聯繫人
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
譯文內容由第三人軟體翻譯。